NVO

Novo Nordisk A/S Healthcare - Pharmaceuticals Investor Relations →

YES
39.0% BELOW
↓ Approaching Was -36.8% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $77.11
14-Week RSI 62
Rel. Volume (14w) This week's trading vs. the 14-week average 1.4x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 1.19

Novo Nordisk A/S (NVO) closed at $47.08 as of 2026-07-31, trading 39.0% below its 200-week moving average of $77.11. This places NVO in the extreme value zone. The stock is currently moving closer to the line, down from -36.8% last week. The 14-week RSI sits at 62, indicating neutral momentum.

Trading volume is running at 1.4x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.19 ratio) is neutral — neither side is clearly dominating.

Over the past 2313 weeks of data, NVO has crossed below its 200-week moving average 19 times. On average, these episodes lasted 20 weeks. Historically, investors who bought NVO at the start of these episodes saw an average one-year return of +14.4%.

With a market cap of $208.2 billion, NVO is a large-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at 71.4%, indicating strong profitability. The stock trades at 6.7x book value.

Over the past 33.6 years, a hypothetical investment of $100 in NVO would have grown to $17256, compared to $3098 for the S&P 500. That represents an annualized return of 16.6% vs 10.8% for the index — confirming NVO as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.

Free cash flow has been declining at a -23.3% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: NVO vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After NVO Crosses Below the Line?

Across 13 historical episodes, buying NVO when it crossed below its 200-week moving average produced an average return of +27.3% after 12 months (median +32.0%), compared to +14.6% for the S&P 500 over the same periods. 85% of those episodes were profitable after one year. After 24 months, the average return was +89.0% vs +25.8% for the index.

Each line shows $100 invested at the moment NVO crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Bean Score Experimental

The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices NVO would reach each dislocation threshold.

Current Bean Score -1.35σ
Current FCF Yield 18.28%
Baseline Yield 24.93%
Historical σ 4.52pp

Dislocation Price Levels

Prices where NVO's Bean Score would hit each σ threshold. Valid until next earnings report (date TBD — last report: 2026-03-31).

LevelσPriceSignal
Deep Value+2σ$27.59Unusually cheap — potential buy zone
Value+1σ$31.91Cheap vs. own history
Fair Value+0σ$37.84Historical mean behavior
Expensive-1σ$46.46Expensive vs. own history
Deep Expensive-2σ$60.17Unusually expensive — potential trim zone

Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end

Data depth: 2 quarterly baselines, 26 price observations — Limited history (4+ quarters preferred for reliability)

Signal Accuracy Collecting Data

The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"

12 / 13 weeks minimum

Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.

Dislocation Scores Experimental

Each score measures deviation from NVO's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.

3 stacked signals: yield, drawdown, sector · earnings quality deteriorating
Yield Dislocation +1.52σ Dividend yield vs own 10-yr norm
Drawdown Score +2.13σ Distance from line vs own history
Sector-Relative +2.22σ Vs sector median this week
Buyback Acceleration +0.4pp YoY share change vs own 3-yr pace (− = accelerating)
Insider Intensity N/A TTM buys / market cap, percentile of buyers
FCF Yield vs History -23.2pp Vs own recent annual mean
Earnings Quality Deteriorating Accrual gap trend (+19.8pp of revenue)

Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.

Historical Touches

NVO has crossed below its 200-week MA 19 times with an average 1-year return of +14.4% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Apr 1984Apr 198412.9%-39.0%+38943.4%
May 1984Aug 19841114.1%-30.0%+41175.4%
Aug 1984Mar 198713253.2%-35.3%+44529.1%
Apr 1987Apr 198730.7%-23.8%+46569.0%
May 1987Jun 198732.1%-19.2%+48309.5%
Aug 1987Jun 19884333.2%+13.4%+52343.6%
Apr 1999May 199910.7%+37.6%+7648.8%
May 1999Jun 199911.0%+68.7%+7581.4%
Apr 2002Apr 200235.8%+14.9%+4784.8%
May 2002Jun 200253.5%+25.0%+4691.0%
Jul 2002Mar 20033628.1%+18.9%+4944.4%
Jul 2003Aug 200312.1%+57.4%+4365.2%
Mar 2009Mar 200910.8%+70.8%+1448.1%
Apr 2009Apr 200920.9%+83.0%+1429.9%
Sep 2016Aug 20174527.1%+19.3%+182.4%
Jun 2018Jun 201822.4%+12.6%+150.2%
Oct 2018Dec 2018137.9%+19.6%+153.2%
Feb 2025Feb 202511.5%-34.6%-35.6%
Mar 2025Ongoing73+55.2%Ongoing-35.0%
Average20+14.4%

Frequently Asked Questions

Is NVO below its 200-week moving average?

Yes. As of 2026-07-31, Novo Nordisk A/S (NVO) is trading 39.0% below its 200-week moving average of $77.11. The current price is $47.08.

What is NVO's 200-week moving average price?

Novo Nordisk A/S's 200-week moving average is $77.11 as of 2026-07-31. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when NVO drops below its 200-week moving average?

NVO has crossed below its 200-week moving average 19 times in our data. On average, buying at that moment produced a one-year return of +14.4%. These dips have historically been decent entry points. These episodes lasted 20 weeks on average.

Is NVO a good value right now?

Here's what our data says about NVO as of 2026-07-31: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 62. Free cash flow is currently negative. Return on equity is 71.4%. Price-to-book is 6.7x. This is not a buy or sell recommendation — always do your own research.

How does NVO compare to the S&P 500?

Over the past 33.6 years, $100 invested in NVO would have grown to $17256, compared to $3098 for the S&P 500. That's 16.6% annualized vs 10.8% for the index. NVO has outperformed the broader market over this period.

Does NVO pay a dividend?

Yes. Novo Nordisk A/S currently pays a dividend yield of 349.00%.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-07-31